{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:25Z","timestamp":1793672965556,"version":"4.5.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41584-020-0491-4","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T15:03:52Z","timestamp":1599231832000},"page":"590-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Transforming clinical trials in rheumatology: towards patient-centric precision medicine"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-5051","authenticated-orcid":false,"given":"Costantino","family":"Pitzalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest H. S.","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"491_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & Mcinnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"491_CR2","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 4, 18001 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"491_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76, 1113\u20131136 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/art.37711","volume":"65","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt, M. E. et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheumatol. 65, 28\u201338 (2013).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","volume":"388","author":"D Porter","year":"2016","unstructured":"Porter, D. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388, 239\u2013247 (2016).","journal-title":"Lancet"},{"key":"491_CR6","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 388, 2763\u20132774 (2016).","journal-title":"Lancet"},{"key":"491_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","volume":"11","author":"JS Smolen","year":"2015","unstructured":"Smolen, J. S. & Aletaha, D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat. Rev. Rheumatol. 11, 276\u2013289 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"491_CR8","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/kem075","volume":"46","author":"MH Buch","year":"2007","unstructured":"Buch, M. H., Bingham, S. J., Bryer, D. & Emery, P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 46, 1153\u20131156 (2007).","journal-title":"Rheumatology"},{"key":"491_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/rheumatology\/ker300","volume":"51","author":"PP Tak","year":"2012","unstructured":"Tak, P. P. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 51, 600\u2013609 (2012).","journal-title":"Rheumatology"},{"key":"491_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis, M. J. et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 28, 2455\u20132470.e5 (2019).","journal-title":"Cell Rep."},{"key":"491_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby, F. et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann. Rheum. Dis. 78, 761\u2013772 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR12","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera, G. et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann. Rheum. Dis. 78, 1642\u20131652 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR13","first-page":"1","volume":"919","author":"WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium","year":"2003","unstructured":"WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ. Tech. Rep. Ser. 919, 1\u2013218 (2003).","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"491_CR14","first-page":"707","volume":"244","author":"K Goutsouliak","year":"2019","unstructured":"Goutsouliak, K. et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat. Rev. Clin. Oncol. 244, 707\u2013718 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"491_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"491_CR16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685\u2013699 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","volume":"55","author":"BVJ Cuppen","year":"2016","unstructured":"Cuppen, B. V. J. et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology 55, 826\u2013839 (2016).","journal-title":"Rheumatology"},{"key":"491_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000615","volume":"4","author":"PC Taylor","year":"2018","unstructured":"Taylor, P. C. et al. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. RMD Open 4, e000615 (2018).","journal-title":"RMD Open"},{"key":"491_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/annrheumdis-2019-216529","volume":"79","author":"P Studenic","year":"2020","unstructured":"Studenic, P. et al. Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR\/EULAR Boolean criteria optimal? Ann. Rheum. Dis. 79, 445\u2013452 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/annrheumdis-2016-210283","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen, B. et al. Discordance between tender and swollen joint count as well as patient\u2019s and evaluator\u2019s global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Ann. Rheum. Dis. 76, 708\u2013711 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/rheumatology\/kez049","volume":"58","author":"EMA Hensor","year":"2019","unstructured":"Hensor, E. M. A. et al. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology 58, 1400\u20131409 (2019).","journal-title":"Rheumatology"},{"key":"491_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","volume":"74","author":"Y Tanaka","year":"2015","unstructured":"Tanaka, Y. et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann. Rheum. Dis. 74, 389\u2013395 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3899\/jrheum.190102","volume":"47","author":"EC Keystone","year":"2020","unstructured":"Keystone, E. C. et al. Toward defining primary and secondary nonresponse in rheumatoid arthritis patients treated with anti-TNF: results from the BioTRAC and OBRI registries. J. Rheumatol. 47, 510\u2013517 (2020).","journal-title":"J. Rheumatol."},{"key":"491_CR24","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin, S. et al. Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway. Ann. Rheum. Dis. 71, 1741\u20131748 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand, V. et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31, 299\u2013316 (2017).","journal-title":"BioDrugs"},{"key":"491_CR26","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/rheumatology\/ken261","volume":"47","author":"MH Buch","year":"2008","unstructured":"Buch, M. H. et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology 47, 1469\u20131475 (2008).","journal-title":"Rheumatology"},{"key":"491_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12891-015-0831-8","volume":"16","author":"K Kumar","year":"2015","unstructured":"Kumar, K. et al. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. BMC Musculoskelet. Disord. 16, 311\u2013396 (2015).","journal-title":"BMC Musculoskelet. Disord."},{"key":"491_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrrheum.2013.5","volume":"9","author":"MH Buch","year":"2013","unstructured":"Buch, M. H., Pavitt, S., Parmar, M. & Emery, P. Creative trial design in RA: optimizing patient outcomes. Nat. Rev. Rheumatol. 9, 183\u2013194 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"491_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/BOR.0b013e32835fd8eb","volume":"25","author":"C Pitzalis","year":"2013","unstructured":"Pitzalis, C., Kelly, S. & Humby, F. New learnings on the pathophysiology of RA from synovial biopsies. Curr. Opin. Rheumatol. 25, 334\u2013344 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"491_CR30","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/art.40070","volume":"69","author":"FJ Blanco","year":"2017","unstructured":"Blanco, F. J. et al. Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study. Arthritis Rheumatol. 69, 1144\u20131153 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13075-015-0688-0","volume":"17","author":"JD Ca\u00f1ete","year":"2015","unstructured":"Ca\u00f1ete, J. D. et al. Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res. Ther. 17, 173 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"491_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.semarthrit.2016.07.006","volume":"46","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann, R., Landew\u00e9, R. & Smolen, J. S. Review of head-to-head study designs in rheumatoid arthritis. Semin. Arthritis Rheum. 46, 279\u2013285 (2016).","journal-title":"Semin. Arthritis Rheum."},{"key":"491_CR33","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acr.22860","volume":"68","author":"P Vashisht","year":"2016","unstructured":"Vashisht, P., Sayles, H., Cannella, A. C., Mikuls, T. R. & Michaud, K. Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res. 68, 1478\u20131488 (2016).","journal-title":"Arthritis Care Res."},{"key":"491_CR34","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s13063-019-3579-x","volume":"20","author":"JJH Park","year":"2019","unstructured":"Park, J. J. H. et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20, 510\u2013572 (2019).","journal-title":"Trials"},{"key":"491_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs, J. D. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. 72, 329\u2013336 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"DM Gerlag","year":"2019","unstructured":"Gerlag, D. M. et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann. Rheum. Dis. 78, 179\u2013185 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/rheumatology\/key069","volume":"58","author":"I Miyagawa","year":"2019","unstructured":"Miyagawa, I. et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology 58, 336\u2013344 (2019).","journal-title":"Rheumatology"},{"key":"491_CR38","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar2678","volume":"11","author":"V Badot","year":"2009","unstructured":"Badot, V. et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res. Ther. 11, R57 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"491_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13075-016-0919-z","volume":"18","author":"A De Groof","year":"2016","unstructured":"De Groof, A. et al. Higher expression of TNF\u03b1-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy. Arthritis Res. Ther. 18, 19 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"491_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.38202","volume":"66","author":"J Ducreux","year":"2013","unstructured":"Ducreux, J. et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 66, 15\u201323 (2013).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR41","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/art.30292","volume":"63","author":"I Gutierrez-Roelens","year":"2011","unstructured":"Gutierrez-Roelens, I. et al. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis Rheumatol. 63, 1246\u20131254 (2011).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR42","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","volume":"71","author":"VE Hogan","year":"2012","unstructured":"Hogan, V. E. et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann. Rheum. Dis. 71, 1888\u20131894 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR43","unstructured":"EU Clinical Trials Register. EudraCT number: 2014-003529-16. European Medicines Agency https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2014-003529-16 (2020)."},{"key":"491_CR44","unstructured":"EU Clinical Trials Register. ClinicalTrialsRegister.eu, EudraCT number: 2012-002535-28. European Medicines Agency https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-002535-28 (2020)."},{"key":"491_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/annrheumdis-2013-204603","volume":"74","author":"S Kelly","year":"2015","unstructured":"Kelly, S. et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann. Rheum. Dis. 74, 611\u2013617 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000799","volume":"4","author":"SA Just","year":"2018","unstructured":"Just, S. A. et al. Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. RMD Open 4, e000799 (2018).","journal-title":"RMD Open"},{"key":"491_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm7010001","volume":"7","author":"M Antoniou","year":"2017","unstructured":"Antoniou, M., Kolamunnage-Dona, R. & Jorgensen, A. L. Biomarker-guided non-adaptive trial designs in phase II and phase III: a methodological review. J. Pers. Med. 7, 1 (2017).","journal-title":"J. Pers. Med."},{"key":"491_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149803","volume":"11","author":"M Antoniou","year":"2016","unstructured":"Antoniou, M., Jorgensen, A. L. & Kolamunnage-Dona, R. Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review. PLoS ONE 11, e0149803 (2016).","journal-title":"PLoS ONE"},{"key":"491_CR49","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F","volume":"43","author":"AK Ulfgren","year":"2000","unstructured":"Ulfgren, A. K. et al. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. 43, 2391\u20132396 (2000).","journal-title":"Arthritis Rheum."},{"key":"491_CR50","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis","year":"2014","unstructured":"Dennis, G. et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16, R90 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"491_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature15819","volume":"526","author":"AV Biankin","year":"2015","unstructured":"Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361\u2013370 (2015).","journal-title":"Nature"},{"key":"491_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","volume":"9","author":"EH Choy","year":"2013","unstructured":"Choy, E. H., Kavanaugh, A. F. & Jones, S. A. The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9, 154\u2013163 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"491_CR53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","volume":"29","author":"A Ogata","year":"2019","unstructured":"Ogata, A., Kato, Y., Higa, S. & Yoshizaki, K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod. Rheumatol. 29, 258\u2013267 (2019).","journal-title":"Mod. Rheumatol."},{"key":"491_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper, J., Porter-Brown, B., Thompson, L., Harari, O. & Dougados, M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. 73, 95\u2013100 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR55","first-page":"2205","volume":"365","author":"D Wu","year":"2019","unstructured":"Wu, D. et al. Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naive or tumor necrosis factor inhibitor inadequate responders. Clin. Rheumatol. 365, 2205\u20132210 (2019).","journal-title":"Clin. Rheumatol."},{"key":"491_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen, J. S. et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann. Rheum. Dis. 76, 831\u2013839 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR57","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy, D., Hermann, K.-G. A., Callhoff, J., Listing, J. & Sieper, J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 73, 817\u2013823 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71, 258\u2013270 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR59","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 77, 1295\u20131302 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR60","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/ard.2009.121657","volume":"69","author":"G Schett","year":"2010","unstructured":"Schett, G. & Firestein, G. S. Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann. Rheum. Dis. 69, 787\u2013789 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR61","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1136\/annrheumdis-2016-209275","volume":"75","author":"M Merashli","year":"2016","unstructured":"Merashli, M., De Marco, G., Podgorski, M., McGonagle, D. & Marzo-Ortega, H. Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. Ann. Rheum. Dis. 75, 1418\u20131420 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"491_CR62","unstructured":"U.S. Food and Drug Administration. Adaptive design clinical trials for drugs and biologics: guidance for industry. FDA https:\/\/www.fda.gov\/media\/78495\/download (2019)."},{"key":"491_CR63","doi-asserted-by":"publisher","first-page":"100493","DOI":"10.1016\/j.conctc.2019.100493","volume":"16","author":"M Antoniou","year":"2019","unstructured":"Antoniou, M. et al. Biomarker-guided trials: challenges in practice. Contemp. Clin. Trials Commun. 16, 100493 (2019).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"491_CR64","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1002\/art.39235","volume":"67","author":"F Humby","year":"2015","unstructured":"Humby, F. et al. Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials. Arthritis Rheumatol. 67, 2601\u20132610 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR65","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/rheumatology\/kew369","volume":"56","author":"A Barton","year":"2017","unstructured":"Barton, A. & Pitzalis, C. Stratified medicine in rheumatoid arthritis-the MATURA programme. Rheumatology 56, 1247\u20131250 (2017).","journal-title":"Rheumatology"},{"key":"491_CR66","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3899\/jrheum.181054","volume":"46","author":"T Pickles","year":"2019","unstructured":"Pickles, T. et al. Adaptive trial designs in rheumatology: report from the OMERACT Special Interest Group. J. Rheumatol. 46, 1406\u20131408 (2019).","journal-title":"J. Rheumatol."},{"key":"491_CR67","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/art.40453","volume":"70","author":"AM Mandelin","year":"2018","unstructured":"Mandelin, A. M. et al. Transcriptional profiling of synovial macrophages using minimally invasive ultrasound-guided synovial biopsies in rheumatoid arthritis. Arthritis Rheumatol. 70, 841\u2013854 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-018-1631-y","volume":"20","author":"LT Donlin","year":"2018","unstructured":"Donlin, L. T. et al. Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue. Arthritis Res. Ther. 20, 139 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"491_CR69","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019).","journal-title":"Nat. Immunol."},{"key":"491_CR70","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.39700","volume":"68","author":"PJ Mease","year":"2016","unstructured":"Mease, P. J. et al. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol. 68, 2163\u20132173 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"491_CR71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40744-017-0086-y","volume":"4","author":"H Tahir","year":"2017","unstructured":"Tahir, H. et al. Secukinumab in active rheumatoid arthritis after anti-TNF\u03b1 therapy: a randomized, double-blind placebo-controlled phase 3 study. Rheumatol. Ther. 4, 475\u2013488 (2017).","journal-title":"Rheumatol. Ther."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0491-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0491-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0491-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T23:11:45Z","timestamp":1630710705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0491-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0491-4","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"4 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}